The most popular stomach-powered drug Fujian Haixi was the first to be evaluated.

Pharmaceutical Network June 23rd, Fujian Haixi new drug creation according to the imitation of 4 categories of declaration of the oxalic acid Moshabili tablets approved production, as through consistency evaluation, as the first in the countryAccording to Minet.com, sales of Moshabili tablets at the end of China's public medical institutions in 2019 were 704 million yuan, ranking first in the competitive landscape of gastric-powered drug products.Mosabili is a highly selective 5-HT4 receptor agonist, with high receptor selection, high safety (
adverse reactions
low, nohearttoxic action), a wide range of action sites (full gastrointestinal power medicine), indications wide and so on, clinically used for functional indigestion, esophageal reflux, gastric palsy, constipation, capsule mirror and so on.Figure 1: 2015-2019 Sales of Moshabili tablets at the end of China's public medical institutions (units: 10,000 yuan)the current domestic market market sales of mosabili tablets, mosabili dispersible tablets, mosabili capsules and saccharin oral solutionAccording to The Data of Minnet.com, sales of Moshabili at the end of China's urban publichospitals
, county-level public hospitals, urban community centers and township hospitals (referred to as china's public medical institutions) in 2019 were 1.219 billion yuan, up 4.63 percent year-on-year, of which sales of mosabili tablets were 704 million yuan.Figure 2: In 2019, the competitive pattern of terminal gastric power drug products in China's public medical institutionsin the competitive pattern of terminal gastric power drug products in public medical institutions in China in 2019, the market share of TOP3 products exceeded 10% The mosabli tablet sat in first place with 30.76 percent of the market share, with the dopone tablet with 24.53 percent of the market share, followed by the mothabili dispersible tablet with 13.14 percent market share in the third place .　　On January 10, 2019, Fujian Haixi New Drug Creation according to the imitation of the 4 categories of declaration of the application for listing of the cesic acid Moshabili tablets received the CDE, has been approved for production, as through the consistency evaluation, as the first in china Sumitomo Pharmaceuticals (Suzhou) products are also reported as imitation 4 categories, currently in the "in the review and approval (in the drug review center)" status .　　In addition, Lunanbet Pharmaceuticals and Chengdu Kanghong Pharmaceuticals have submitted additional applications for consistency evaluation of mosabili tablets, and are currently in the "in the review and approval (in the drug review center)" status .　　Source: Minnet database Note: statistics as of June 22, if there are omissions, welcome to point! .